pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Castration Resistant Prostate Cancer
- Metastatic Cancer
- Prostate Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: 1:1 randomized, open-label, multi-institution phase II trialMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04090528
- Collaborators
- Merck Sharp & Dohme Corp.
- Madison Vaccines, Inc
- Prostate Cancer Foundation
- Investigators
- Principal Investigator: Douglas McNeel, MD, PhD University of Wisconsin, Madison